In the group with high MLPH expression, we also observed a tumor regression grade of 0–1 in 30 (17.4%) patients, grade 2–3 in 51 (29.7%) patients, and grade 4 in 5 (2.9%) patients, indicating that MLPH expression plays an important role in the aggressive behavior of rectal tumors and their sensitivity to chemoradiation. The gene discussed is MLPH; the disease is rectal neoplasm.